Blockade of IL-33 Release and Suppression of Type 2 Innate Lymphoid Cell Responses by Helminth Secreted Products in Airway Allergy
Overview
Affiliations
Helminth parasites such as the nematode Heligmosomoides polygyrus strongly inhibit T helper type 2 (Th2) allergy, as well as colitis and autoimmunity. Here, we show that the soluble excretory/secretory products of H. polygyrus (HES) potently suppress inflammation induced by allergens from the common fungus Alternaria alternata. Alternaria extract, when administered to mice intranasally with ovalbumin (OVA) protein, induces a rapid (1-48 h) innate response while also priming an OVA-specific Th2 response that can be evoked 14 days later by intranasal administration of OVA alone. In this model, HES coadministration with Alternaria/OVA suppressed early IL-33 release, innate lymphoid cell (ILC) production of IL-4, IL-5, and IL-13, and localized eosinophilia. Upon OVA challenge, type 2 ILC (ILC2)/Th2 cytokine production and eosinophilia were diminished in HES-treated mice. HES administration 6 h before Alternaria blocked the allergic response, and its suppressive activity was abolished by heat treatment. Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. Thus, this helminth parasite targets IL-33 production as part of its armory of suppressive effects, forestalling the development of the type 2 immune response to infection and allergic sensitization.
Wu F, Chen Y, Chen X, Tong D, Zhou J, Du Z Commun Biol. 2025; 8(1):356.
PMID: 40032982 PMC: 11876351. DOI: 10.1038/s42003-025-07803-8.
Structural basis for IL-33 recognition and its antagonism by the helminth effector protein HpARI2.
Jamwal A, Colomb F, McSorley H, Higgins M Nat Commun. 2024; 15(1):5226.
PMID: 38890291 PMC: 11189471. DOI: 10.1038/s41467-024-49550-0.
Schmitt P, Duval A, Camus M, Lefrancais E, Roga S, Dedieu C J Exp Med. 2024; 221(6).
PMID: 38597952 PMC: 11010340. DOI: 10.1084/jem.20231236.
Colomb F, Ogunkanbi A, Jamwal A, Dong B, Maizels R, Finney C Infect Immun. 2024; 92(3):e0039523.
PMID: 38294241 PMC: 10929406. DOI: 10.1128/iai.00395-23.
Extracellular derivatives for bone metabolism.
Wu Y, Song P, Wang M, Liu H, Jing Y, Su J J Adv Res. 2024; 66:329-347.
PMID: 38218580 PMC: 11674789. DOI: 10.1016/j.jare.2024.01.011.